Potent EGFR/PARP-1 inhibition by spirooxindole-triazole hybrids for targeted liver cancer therapy.
Nafie MS, Ali M, Alwehaibi MA, Alayyaf AA, Al-Muhanna MK, Almuqati NS, Alghamdi AA, Haukka M, Tariq SS, Ul-Haq Z, Barakat A.
Nafie MS, et al. Among authors: al muhanna mk.
RSC Adv. 2025 Jan 3;15(1):58-74. doi: 10.1039/d4ra05966b. eCollection 2025 Jan 2.
RSC Adv. 2025.
PMID: 39763621
Free PMC article.